德国住院恶性胶质瘤患者的姑息治疗
该横断面回顾性研究分析德国医院补偿系统2019至2022年数据,纳入101192例恶性胶质瘤住院病例,发现6129例(6%)院内死亡、2798例(2.8%)转至临终关怀机构、10592例(10.5%)接受复杂或专科姑息治疗;院内死亡病例中2479/6129例(40.4%)接受专科姑息治疗。
要点
- 2019至2022年恶性胶质瘤住院病例中10.5%接受复杂或专科姑息治疗。
- 院内死亡病例中40.4%(2479/6129)接受专科姑息治疗。
- 65岁以下患者及男性患者接受复杂或专科姑息治疗频率显著更低。
核心结论
- 尽管恶性胶质瘤预后差且症状复杂,仅约10%的住院恶性胶质瘤患者和约40%的院内死亡患者接受了复杂或专科姑息治疗。
- 作者认为这一差距凸显了扩大该患者群体姑息治疗可及性的迫切需求,并强调需进一步研究以识别和解决阻碍更广泛实施姑息治疗的障碍。
研究设计与样本
- 横断面回顾性研究,分析德国医院补偿系统研究所(InEK GmbH,Siegburg,Germany)2019至2022年数据。
- 纳入主要或次要诊断为C71(恶性胶质瘤)的患者,排除主要和次要诊断双重编码的病例以避免重复计数。
- 共纳入101192例恶性胶质瘤住院病例。
主要发现
- 2019至2022年101192例恶性胶质瘤住院病例中,6129例(6%)发生院内死亡,2798例(2.8%)转至临终关怀机构。
- 10592例(10.5%)接受了复杂或专科姑息医疗,该提供率在COVID-19大流行期间保持不变。
- 65岁以下患者接受复杂或专科姑息治疗频率显著更低(p < 0.0001),男性患者亦显著更低(padjusted = 0.016)。
- 恶性胶质瘤院内死亡病例中,2479/6129例(40.4%)接受了专科姑息治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Malignant gliomas impose a significant symptomatic burden on patients and their families. Current guidelines recommend palliative care for patients with advanced tumors within eight weeks of diagnosis, emphasizing early integration for malignant glioma cases. However, the utilization rate of palliative care for these patients in Germany remains unquantified. This study investigates the proportion of malignant glioma patients who either died in a hospital or were transferred to hospice care from 2019 to 2022, and the prevalence of in-patient specialized palliative care interventions. METHODS: In this cross-sectional, retrospective study, we analyzed data from the Institute for the Hospital Remuneration System (InEK GmbH, Siegburg, Germany), covering 2019 to 2022. We included patients with a primary or secondary diagnosis of C71 (malignant glioma) in our analysis. To refine our dataset, we identified cases with dual-coded primary and secondary diagnoses and excluded these to avoid duplication in our final tally. The data extraction process involved detailed scrutiny of hospital records to ascertain the frequency of hospital deaths, hospice transfers, and the provision of complex or specialized palliative care for patients with C71-coded diagnoses. Descriptive statistics and inferential analyses were employed to evaluate the trends and significance of the findings. RESULTS: From 2019 to 2022, of the 101,192 hospital cases involving malignant glioma patients, 6,129 (6% of all cases) resulted in in-hospital mortality, while 2,798 (2.8%) led to hospice transfers. Among these, 10,592 cases (10.5% of total) involved the administration of complex or specialized palliative medical care. This provision rate remained unchanged throughout the COVID-19 pandemic. Notably, significantly lower frequencies of complex or specialized palliative care implementation were observed in patients below 65 years (p < 0.0001) and in male patients (padjusted = 0.016). In cases of in-hospital mortality due to malignant gliomas, 2,479 out of 6,129 cases (40.4%) received specialized palliative care. CONCLUSION: Despite the poor prognosis and complex symptomatology associated with malignant gliomas, only a small proportion of affected patients received advanced palliative care. Specifically, only about 10% of hospitalized patients with malignant gliomas, and approximately 40% of those who succumb to the disease in hospital settings, were afforded complex or specialized palliative care. This discrepancy underscores an urgent need to expand palliative care access for this patient demographic. Additionally, it highlights the importance of further research to identify and address the barriers preventing wider implementation of palliative care in this context.
引用
- Fink L, van Oorschot B, von Saß C, et al. Palliative care for in-patient malignant glioma patients in Germany. J Neurooncol. 2024. PMID: 38506960. doi:10.1007/s11060-024-04611-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。